China Money Network
Login
Join

Temasek Leads $59M Round In Chinese Biotherapeutics Developer Just China

  • August 8, 2017 — 11:25 CST

This Data Is Locked!

This area is available only to Subscribers.

Singapore’s state investment firm Temasek Holdings has led a RMB400 million(US$59 million) series B round in Hangzhou Just Bioteherapeutics Ltd., a Chinese antibody and recombinant... [DATA LOCKED]

UNLOCK DATA

Follow the Money & Subscribe for Access to the Best Data and Intelligence on Chinese Venture Capital Deals

Join

Access Thousands of Data Points to Monitor Chinese Private Equity Deal Movement and Relationships

Already Have an Account?

Login
Related Topics:

Related Data: